FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4307968712> ?p ?o ?g. }

• W4307968712 endingPage "152660282211314" @default.
• W4307968712 startingPage "152660282211314" @default.
• W4307968712 abstract "Current endovascular treatments of below the knee (BTK) popliteal or tibial/peroneal arteries including investigational drug-coated balloons have limited long-term efficacy.This Phase 2 trial assessed the feasibility of adventitial deposition of temsirolimus to reduce neointimal hyperplasia and clinically relevant target lesion failure (CR-TLF) 6 months after BTK arterial revascularization.This prospective, multicenter, double-blinded, comparative, dose-escalation trial enrolled 61 patients with Rutherford 3 to 5 symptoms undergoing endovascular revascularization of ≥1 angiographically significant BTK lesions. Perivascular infusion after completion of arterial revascularization was randomized into control (saline) vs low-dose (0.1 mg/mL) temsirolimus groups for the first 30 patients. In the second part of the trial, patients were randomized to control versus high-dose (0.4 mg/mL) temsirolimus groups. Primary and secondary efficacy endpoints were target lesion (TL) transverse-view vessel area loss percentage (TVAL%) and CR-TLF at 6 months, respectively. CR-TLF was defined as a composite of ischemia-driven major amputation of the target limb, clinically driven target lesion revascularization (CD-TLR), and clinically relevant TL occlusion. The primary safety endpoint was freedom from major adverse limb events or perioperative death (MALE+POD) at 30 days.There was no discernable difference in effect between temsirolimus doses; therefore, the low- and high-dose cohorts were pooled for the analyses. The principal analysis on the per protocol (PP) group of 53 patients revealed superior primary efficacy of the treatment arm, with reduction in TVAL% of 13.9% absolute (37.3% relative) and the rate of CR-TLF reduced by 27.1% absolute (51.3% relative), at 6 months. Subgroup analysis of all Trans-Atlantic Inter-Society Consensus (TASC) B to D lesions (N=36) revealed TVAL% reduction of 22.3% absolute (48.3% relative) and the rate of CR-TLF reduced by 39.2% absolute (56.6% relative). Freedom from 30-day MALE+POD was 100% in all groups.This hypothesis-generating trial suggests that adventitial infusion of temsirolimus in BTK arteries improves TVAL% and CR-TLF with no adverse safety signals through 6 months, supporting the move to a Phase 3 trial.There remain gaps in the endovascular treatment of patients with atherosclerotic lesions of below-the-knee (BTK) arteries. The TANGO trial evaluated the use of sub-adventitial temsirolimus with the Bullfrog micro-infusion device during BTK interventions. The therapy was safe and effective. Compared with controls, vessel lumen area patency was improved, and target lesion failure was less frequent. The effects were most appreciable in subjects with higher baseline TASC lesions (B, C, or D). Sub-adventitial temsirolimus offers the potential to improve the results of BTK interventions in this challenging patient population." @default.
• W4307968712 created "2022-11-06" @default.
• W4307968712 creator A5020558019 @default.
• W4307968712 creator A5023858684 @default.
• W4307968712 creator A5026181456 @default.
• W4307968712 creator A5037597901 @default.
• W4307968712 creator A5039664422 @default.
• W4307968712 creator A5069400507 @default.
• W4307968712 creator A5080854123 @default.
• W4307968712 creator A5083180060 @default.
• W4307968712 date "2022-11-01" @default.
• W4307968712 modified "2023-10-16" @default.
• W4307968712 title "Temsirolimus Adventitial Delivery to Improve ANGiographic Outcomes Below the Knee" @default.
• W4307968712 cites W1977671695 @default.
• W4307968712 cites W1983032329 @default.
• W4307968712 cites W1984684769 @default.
• W4307968712 cites W1998815954 @default.
• W4307968712 cites W2030619949 @default.
• W4307968712 cites W2053492914 @default.
• W4307968712 cites W2067229002 @default.
• W4307968712 cites W2104216156 @default.
• W4307968712 cites W2105919751 @default.
• W4307968712 cites W2118501388 @default.
• W4307968712 cites W2163126697 @default.
• W4307968712 cites W2502563256 @default.
• W4307968712 cites W2739447339 @default.
• W4307968712 cites W2800326626 @default.
• W4307968712 cites W2887936019 @default.
• W4307968712 cites W2903350476 @default.
• W4307968712 cites W3000556138 @default.
• W4307968712 cites W3183730974 @default.
• W4307968712 cites W72878636 @default.
• W4307968712 doi "https://doi.org/10.1177/15266028221131459" @default.
• W4307968712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36320143" @default.
• W4307968712 hasPublicationYear "2022" @default.
• W4307968712 type Work @default.
• W4307968712 citedByCount "0" @default.
• W4307968712 crossrefType "journal-article" @default.
• W4307968712 hasAuthorship W4307968712A5020558019 @default.
• W4307968712 hasAuthorship W4307968712A5023858684 @default.
• W4307968712 hasAuthorship W4307968712A5026181456 @default.
• W4307968712 hasAuthorship W4307968712A5037597901 @default.
• W4307968712 hasAuthorship W4307968712A5039664422 @default.
• W4307968712 hasAuthorship W4307968712A5069400507 @default.
• W4307968712 hasAuthorship W4307968712A5080854123 @default.
• W4307968712 hasAuthorship W4307968712A5083180060 @default.
• W4307968712 hasConcept C126322002 @default.
• W4307968712 hasConcept C126894567 @default.
• W4307968712 hasConcept C141071460 @default.
• W4307968712 hasConcept C168563851 @default.
• W4307968712 hasConcept C183713625 @default.
• W4307968712 hasConcept C185592680 @default.
• W4307968712 hasConcept C190283241 @default.
• W4307968712 hasConcept C197934379 @default.
• W4307968712 hasConcept C203092338 @default.
• W4307968712 hasConcept C2776820818 @default.
• W4307968712 hasConcept C2779464278 @default.
• W4307968712 hasConcept C2780400711 @default.
• W4307968712 hasConcept C2781099653 @default.
• W4307968712 hasConcept C2781464078 @default.
• W4307968712 hasConcept C500558357 @default.
• W4307968712 hasConcept C55493867 @default.
• W4307968712 hasConcept C71924100 @default.
• W4307968712 hasConcept C75217442 @default.
• W4307968712 hasConceptScore W4307968712C126322002 @default.
• W4307968712 hasConceptScore W4307968712C126894567 @default.
• W4307968712 hasConceptScore W4307968712C141071460 @default.
• W4307968712 hasConceptScore W4307968712C168563851 @default.
• W4307968712 hasConceptScore W4307968712C183713625 @default.
• W4307968712 hasConceptScore W4307968712C185592680 @default.
• W4307968712 hasConceptScore W4307968712C190283241 @default.
• W4307968712 hasConceptScore W4307968712C197934379 @default.
• W4307968712 hasConceptScore W4307968712C203092338 @default.
• W4307968712 hasConceptScore W4307968712C2776820818 @default.
• W4307968712 hasConceptScore W4307968712C2779464278 @default.
• W4307968712 hasConceptScore W4307968712C2780400711 @default.
• W4307968712 hasConceptScore W4307968712C2781099653 @default.
• W4307968712 hasConceptScore W4307968712C2781464078 @default.
• W4307968712 hasConceptScore W4307968712C500558357 @default.
• W4307968712 hasConceptScore W4307968712C55493867 @default.
• W4307968712 hasConceptScore W4307968712C71924100 @default.
• W4307968712 hasConceptScore W4307968712C75217442 @default.
• W4307968712 hasLocation W43079687121 @default.
• W4307968712 hasLocation W43079687122 @default.
• W4307968712 hasOpenAccess W4307968712 @default.
• W4307968712 hasPrimaryLocation W43079687121 @default.
• W4307968712 hasRelatedWork W1501701126 @default.
• W4307968712 hasRelatedWork W1979219809 @default.
• W4307968712 hasRelatedWork W1995098598 @default.
• W4307968712 hasRelatedWork W2163955568 @default.
• W4307968712 hasRelatedWork W2551988254 @default.
• W4307968712 hasRelatedWork W2581512623 @default.
• W4307968712 hasRelatedWork W3171977235 @default.
• W4307968712 hasRelatedWork W3203463092 @default.
• W4307968712 hasRelatedWork W4307968712 @default.
• W4307968712 hasRelatedWork W72878636 @default.
• W4307968712 isParatext "false" @default.
• W4307968712 isRetracted "false" @default.

• next